Loading patent…
OwnerDavid Evander ANDERSON, Tanvir AHMED +1inventors
InventorsDavid Evander ANDERSON, Tanvir AHMED, Rohan Aminbhai LALANI
Estimating the term…
An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.
An immunogenic composition comprising mRNA encoding polypeptides that constitute a virus-like particle (VLP), and a pharmaceutically acceptable carrier,
(canceled)
(canceled)
(canceled)
The immunogenic composition of further comprising an adjuvant selected from the group consisting of cytokines, gel-type adjuvants, microbial adjuvants, oil-emulsion and emulsifier-based adjuvants, particulate adjuvants, an aluminum salt, synthetic adjuvants, polymer adjuvants, and combinations thereof.
(canceled)
(canceled)
(canceled)
(canceled)
A method of producing a virus-like particle (VLP) by co-transfecting a host cell with a first vector comprising a nucleotide sequence encoding SEQ ID NO:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.